secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001193125-23-268944
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports Phase 1 data for STAT3 degrader KT-333: one PR in CTCL, no DLTs
------------------------------------------------------------------------------

- 21 patients enrolled through dose level 5; 12 evaluable for disease assessment.
- One partial response in cutaneous T-cell lymphoma (CTCL) at DL2; stable disease in 3 solid tumor patients (DL3/4).
- No dose-limiting toxicities or serious adverse events; most AEs Grade 1/2 (constipation, fatigue, nausea, anemia).
- Dose-dependent, sustained STAT3 degradation in PBMCs at DL3+ at levels linked to preclinical anti-tumor activity.
- Updated data to be presented at ASH 2023 on December 10.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/0001193125-23-268944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312523268944/d590090d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer